IP Library Granted Patent US 11,471,262
Granted Patent B2
US 11,471,262 · App. 16/717,164 · Granted Oct 18, 2022

Methods for targeting a body passage to effect fluid flow

Inventors: Robert Julian Dickinson (London, GB); Roberto Ferraresi (Milan, IT); Steven Kum (Singapore, SG); Timothy Lenihan (Hradec Kralove, CZ); Andrew Robert Pacey (Stevenage, GB); Martin Terry Rothman (Santa Rosa, CA)
Assignee: LimFlow Gmbh
A61F2/07A61B8/0841A61B8/12A61B17/11A61B17/22A61B17/3478A61B18/245A61F2/064A61F2/844A61F2/90A61F2/95A61F2/958A61M27/002A61B18/1492A61B2017/00252A61B2017/1103A61B2017/1107A61B2017/1139A61B2017/22095A61B2017/22097A61B2034/2063A61F2/915A61F2/962A61F2002/068A61F2230/0067A61F2230/0069A61F2250/001A61F2250/0017A61F2250/0029A61F2250/0031A61F2250/0039
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,471,262
App. No.
16/717,164
Granted
Oct 18, 2022
Kind
B2
Abstract

A device includes a first end portion, a second end portion, an intermediate portion, and a graft material. The first end portion has a first end diameter. The second end portion has a second end diameter smaller than the first end diameter. The first end portion comprises a first material. The second end portion comprises a second material different than the first material. The intermediate portion is between the first end portion and the second end portion. The intermediate portion tapers between the first end portion and the second end portion. The graft material is coupled to at least the intermediate portion.

Claims (62)

1. A method of targeting a second passage from a first passage to effect retroperfusion in the second passage, the method comprising:

expanding an expandable device in the second passage;

advancing a needle from a first catheter in the first passage out of the first passage and into the second passage to form a fistula between the first passage and the second passage, wherein advancing the needle comprises puncturing the expandable device; and

making a valve in the second passage incompetent to reduce inhibition of retroperfusion through the second passage by the valve,

wherein, after advancing the needle, a first portion of the needle is in the first passage, a second portion of the needle is in the second passage, and a third portion of the needle is in the fistula.

2. The method of claim 1 , further comprising orienting the needle towards the expandable device.

3. The method of claim 1 , wherein the first passage comprises a tibial artery, and wherein the second passage comprises a tibial vein.

4. The method of claim 1 , wherein expanding the expandable device comprises self-expanding the expandable device.

5. The method of claim 1 , wherein making the valve in the second passage incompetent comprises using a cutting balloon or valvulotome.

6. The method of claim 1 , further comprising:

injecting contrast in the second passage; and

monitoring the contrast using fluoroscopy,

wherein disturbance of the contrast attributable to the needle advancing into the second passage confirms advancement of the needle into the second passage.

7. The method of claim 1 , further comprising:

orienting the needle towards the expandable device;

injecting contrast in the second passage; and

monitoring the contrast using fluoroscopy,

wherein disturbance of the contrast attributable to the needle advancing into the second passage confirms advancement of the needle into the second passage,

wherein the first passage comprises a tibial artery, and

wherein the second passage comprises a tibial vein.

8. A method of targeting a second passage from a first passage to effect retroperfusion in the second passage, the method comprising:

expanding an expandable device in the second passage, the expandable device comprising radiopaque material visible under fluoroscopy;

advancing a needle from a first catheter in the first passage out of the first passage and into the second passage to form a fistula between the first passage and the second passage,

wherein advancing the needle comprises:

targeting the expandable device under fluoroscopy; and

monitoring the needle to confirm advancement of the needle into the second passage; and

making a valve in the second passage incompetent to reduce inhibition of retroperfusion through the second passage by the valve.

9. The method of claim 8 , further comprising orienting the needle towards the expandable device.

10. The method of claim 8 , wherein the first passage comprises a tibial artery, and wherein the second passage comprises a tibial vein.

11. The method of claim 8 , wherein making the valve in the second passage incompetent comprises using a cutting balloon or valvulotome.

12. The method of claim 8 , further comprising injecting contrast in the second passage, wherein monitoring the needle to confirm advancement comprises:

monitoring the contrast using fluoroscopy, and

monitoring disturbance of the contrast attributable to the needle advancing into the second passage.

13. The method of claim 8 , further comprising:

orienting the needle towards the expandable device; and

injecting contrast in the second passage,

wherein monitoring the needle to confirm advancement comprises:

monitoring the contrast using fluoroscopy, and

monitoring disturbance of the contrast attributable to the needle advancing into the second passage,

wherein the first passage comprises a tibial artery, and

wherein the second passage comprises a tibial vein.

14. A method of targeting a second passage from a first passage to effect retroperfusion in the second passage, the method comprising:

inserting an expandable device in the second passage;

advancing a needle from a first catheter in the first passage out of the first passage and into the second passage to form a fistula between the first passage and the second passage, wherein advancing the needle comprises targeting the expandable device;

monitoring the expandable device as the needle is advanced towards the expandable device to confirm advancement of the needle into the second passage; and

making a valve in the second passage incompetent to reduce inhibition of retroperfusion through the second passage by the valve.

15. The method of claim 14 , further comprising orienting the needle towards the expandable device.

16. The method of claim 14 , wherein the first passage comprises a tibial artery, and wherein the second passage comprises a tibial vein.

17. The method of claim 14 , wherein making the valve in the second passage incompetent comprises using a cutting balloon or valvulotome.

18. The method of claim 14 , wherein the expandable device comprises radiopaque material.

19. The method of claim 14 , further comprising:

orienting the needle towards the expandable device;

injecting contrast in the second passage; and

monitoring the contrast,

wherein disturbance of the contrast attributable to the needle advancing into the second passage confirms advancement of the needle into the second passage.

20. The method of claim 14 , further comprising:

injecting contrast in the second passage; and

monitoring the contrast using fluoroscopy,

wherein disturbance of the contrast attributable to the needle advancing into the second passage confirms advancement of the needle into the second passage,

wherein the expandable device comprises radiopaque material,

wherein the first passage comprises a tibial artery, and

wherein the second passage comprises a tibial vein.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2024
From: LIMFLOW S.A.
To: INARI MEDICAL, INC.
Reel/Frame 066380/0110 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2021
From: DICKINSON, ROBERT JULIAN; FERRARESI, ROBERTO; KUM, STEVEN; LENIHAN, TIMOTHY; PACEY, ANDREW ROBERT; ROTHMAN, MARTIN TERRY
To: LIMFLOW GMBH
Reel/Frame 055771/0094 →
Continuity (9)
Continuation 16552241 · Aug 27, 2019
Continuation 16410932 · May 13, 2019
Continuation 15648695 · Jul 13, 2017
Continuation 15084999 · Mar 30, 2016
Continuation 14834813 · Aug 25, 2015
Continuation PCTUS2014019607 · Feb 28, 2014
Continuation In Part 13791185 · Mar 8, 2013
Provisional Application 61901753 · Nov 8, 2013
Related Publication 20200214827A1 · Jul 9, 2020
Cited By (4)
US 12,285,182 US 12,594,075 US 12,636,466 US 12,708,503